Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis

@article{Wang2012EffectOL,
  title={Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis},
  author={Jianmiao Wang and B. Nie and Wei Xiong and Y. Xu},
  journal={Journal of Clinical Pharmacy and Therapeutics},
  year={2012},
  volume={37}
}
  • J. Wang, B. Nie, +1 author Y. Xu
  • Published 2012
  • Medicine
  • Journal of Clinical Pharmacy and Therapeutics
What is Known and Objective:  Inhaled long‐acting beta‐agonists have been licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late 1990s, and they improve lung function and symptoms of dyspnoea. However, the evidence that long‐acting beta‐agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta‐analysis was performed to evaluate their effect on the frequency of exacerbations. 
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease
TLDR
Current evidence from clinical studies of the safety and tolerability profile of LABAs supports their long-term use in COPD. Expand
Long-acting beta2-agonists for chronic obstructive pulmonary disease.
TLDR
Moderate-quality evidence showed that LABA treatment improved quality of life on the SGRQ and did not affect the rate of serious adverse events, and combined findings of all studies showed thatLABA therapy did not significantly affect mortality. Expand
Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease
TLDR
The pharmacological properties, clinical efficacy, safety and potential role of the ultra-LABAs in COPD management, which are effective bronchodilators with a prolonged duration of action, are reviewed. Expand
Is ‘GOLD’ standard for the management of COPD in clinical practice?
  • B. Yawn
  • Medicine
  • Drugs in context
  • 2012
TLDR
Therapy can improve QoL, the level of symptoms, functionality and life expectancy, and ICS are used to prevent exacerbations and, in carefully selected patients, may have additional benefits due to exacerbation prevention. Expand
Pharmacotherapies for COPD
  • S. Ejiofor, A. Turner
  • Medicine
  • Clinical medicine insights. Circulatory, respiratory and pulmonary medicine
  • 2013
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were shortExpand
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease
  • K. Beeh
  • Medicine
  • Tuberculosis and respiratory diseases
  • 2016
TLDR
Evidence supports the efficacy of both classes of long-acting bronchodilators as monotherapy in preventing COPD exacerbations, with greater efficacy of LAMA drugs versus LABAs. Expand
The long-acting β2-adrenoceptor agonist olodaterol attenuates pulmonary inflammation
TLDR
The aim of this study was to determine the efficacy of the long‐acting β2‐adrenoceptor agonist olodaterol to inhibit pulmonary inflammation and to elucidate mechanism(s) underlying its anti‐inflammatory actions. Expand
The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease.
TLDR
Novartis is, in addition to bronchodilator-only therapies, developing LABA/inhaled corticosteroids (ICS) combinations to target inflammation, such as QMF149, as well as non-steroid based anti-inflammatory agents against key novel targets. Expand
Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications
TLDR
Evidence-based guidelines stipulate that early detection and prompt treatment of exacerbations are essential to ensure optimal outcomes and to reduce the burden of COPD. Expand
Bronchodilators: current and future.
TLDR
The muscarinic β2-agonist molecules approach likely provides the best opportunity to develop combinations that combine corticosteroids with dual-bronchodilator activities, and thus potentially achieve better efficacy than is apparent with the current combination products that dominate the treatment of COPD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Safety of Long-Acting β-Agonists in Stable COPD
TLDR
This review supports the beneficial effects of the use of LABAs in patients with stable moderate-to-severe COPD, and did not confirm previous data about an increased risk for respiratory deaths, but suggests the superiority of tiotropium over LAB as for the treatment of stable COPD patients. Expand
Pharmacologic Treatments for Chronic Obstructive Pulmonary Disease: A Mixed‐Treatment Comparison Meta‐analysis
TLDR
This study aims to assess the comparative efficacy of pharmacologic agents for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and to establish a smoking cessation protocol for these agents. Expand
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
TLDR
No evidence that one single inhaled drug regimen is more effective than another in reducing exacerbations is found, and long-acting anticholinergics, inhaled corticosteroids, and combination treatment reduced exacerbations significantly compared with long- acting beta-agonists alone, but not if FEV1 was > 40% predicted. Expand
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
TLDR
Tiotropium is an effective, once-daily bronchodilator that reduces dyspnoea and chronic obstructive pulmonary disease exacerbation frequency and improves health status and that will make an important contribution to chronic obstructives pulmonary disease therapy. Expand
Outcomes for COPD pharmacological trials: from lung function to biomarkers
The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronicExpand
Statistical analysis of COPD exacerbations
From the authors: We would like to thank S. Suissa for his letter, which appeared in a recent issue of the European Respiratory Journal 1. We share his interest in the methodology of chronicExpand
Outcomes for COPD pharmacological trials: From lung function to biomarkers.
TLDR
A Task Force on ‘‘Outcomes for COPD pharmacological trials: from lung function to biomarkers’’ to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Expand
Toward a consensus definition for COPD exacerbations.
TLDR
This paper summarizes the discussions of the workshop, "COPD: Working Towards a Greater Understanding," in which the participants proposed the following working definition of an exacerbation of COPD: a sustained worsening of the patient's condition that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD. Expand
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
TLDR
Combination treatment of inhaled long-acting beta2 agonists and corticosteroid combination treatment produces better control of symptoms and lung function, with no greater risk of side-effects than that with use of either component alone, and should be considered for patients with COPD. Expand
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
TLDR
Indacaterol was an effective once-daily bronchodilator and was at least as effective as tiotropium in improving clinical outcomes for patients with COPD. Expand
...
1
2
3
4
5
...